Journal articles

2025

[62] Yu Jeong Kim, Nayoon Park, and Yonghyun Lee* "Advanced Engineering of Natural Products for Targeted Treatments of Inflammatory Bowel Diseases". International Journal of Nanomedicine (IF 6.7, JCR top 10%) manuscript in preparation

[61] Nadine Otterbein, Klara Martinsson, Eva Schmid, Lukas Heinen, Nayoon Park, Heike Danzer, Kerstin Dürholz, Agnus Monica Davis, Yubin Luo, Georg Schett, Rainer Tietze, Yonghyun Lee, Alf Kastbom and Mario M. Zaiss*  "Bilirubin: From Predictive Biomarker to Therapeutic Nanomedicine ". Annals of the Rheumatic Diseases (IF 20.6, JCR Top 2%) . Submitted

[60] Nayoon Park, Bom Lee, Mina Song, Suyeon Park, Seong-Eun Kim, Dongkyu Lee, and Yonghyun Lee* "Inulin-Butyrate Nanogel for Modulation of Gut Microbiome and Regulatory T-cells in Colitis". Small (IF 12.1) Under Peer-reviewing

[59] Bom Lee, Jeeeun Yoo, Yu Jeong Kim, James J. Moon*, and Yonghyun Lee* "Methylprednisolone-loaded Hyaluronic acid-bilirubin nanomedicine for targeted and synergistic modulation of gut microbiome, intestinal barrier, and immune systems." Small  (IF 12.1), Under Peer-reviewing

[58] Ho Seung Kim, Jinsu Kim, Bom Lee; Yonghyun Lee, So-Yeon Park, Bo-Young Oh, Kyung-Ah Cho, Soon Sup Chung, and Gyoung Tae Noh. "Role of tumor microenvironment in the development of cancer cachexia" Plos One, Submitted (IF 2.6), 

[57] Bom Lee1, Jeeeun Yoo1, Han Sol Lee, and Yonghyun Lee* "Targeted-immunomodulatory Nanomedicine for Treatment of Autoimmune Diseases" International Journal of Nanomedicine, (IF 6.7, JCR top 10%), Under revision.  1These authors contributed equally to this work.

[56] Xiaoliang Cheng, Nayoon Park, and Yonghyun Lee* "Nanoparticles for delivery of metal ions to induce programmed cell death and enhance efficacy of cancer immunotherapy." International Journal of Nanomedicine, (IF 6.7, JCR top 10%), under revision

[55] Xiaoliang Cheng, Haiyan Dong, and Yonghyun Lee*,* "Application of pharmacometrics in antibody-drug conjugate drug development" Journal of Pharmaceutical Investigation, (IF 5.2, JCR top 10%) under revision

[54] Junshen Xue, Yonghyun Lee*, and Tianyan Zhou* "Quantitative Systems Pharmacology Models: Unleashing Their Potential in Cancer Immunotherapy" Journal of Pharmaceutical Investigation, (IF 5.2, JCR top 10%) under revision

[53] Qingyu Yao, Yonghyun Lee*, and Tianyan Zhou* "Pharmacokinetic/pharmacodynamic modeling of therapeutic antibodies in oncology: current advances and future perspectives" Journal of Pharmaceutical Investigation, (IF 5.2, JCR top 10%) 2025 Oct 29, [Link]

[52] Xiaoliang Cheng, Peixing Wang, Hongquang Lyu, Yonghyun Lee*, Juyoung Yoon*, and Haiyan Dong* "Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance". Cancer Drug Resistance, (IF 5.2). 2025 Sep 2, [Link]

[51] Yonghyun Lee* "Topical Nanomedicines Using Lipids, Carbohydrates, Proteins, and Synthetic Polymers for Enhanced Management of Skin Disorders" Journal of Pharmaceutical Investigation, (IF 5.2, JCR top 10%) 2025 June 30, [Link]

[50] Xiner Yi, Xinru Zhang, Yuanye Guan, Yizhe Sha, Xiaoliang Cheng*, Yonghyun Lee*, and Wei-En Yuan* "Nanodrug Delivery System for Precision Treatment of Pulmonary Fibrosis" Precision Medicine and Engineering, 2025 Mar 21, [Link]

2024

[49] Seonju Lee, Seon Ah Lee, Jongyoon Shinn, and Yonghyun Lee* "Hyaluronic acid-bilirubin Nanomedicine as a Tumor Microenvironment-responsive Nanomedicine for Targeted Cancer Therapy" International Journal of Nanomedicine, 2024 May 27 (IF 8.0., JCR top 5%) [Link]

[48] Jinseong Kim, Man Kyu Shim, Yujeong Moon, Jeongrae Kim, Hanhee Cho, Wan Su Yoon, Nayeon Shim, Joon-Kyung Seong, Yonghyun Lee,  Dong-Kwon Lim and Kwangmeyung Kim* "Cancer Cell-Specific and Pro-Apoptotic SMAC Peptide-Doxorubicin Conjugated Prodrug Encapsulated Aposomes for Synergistic Cancer Immunotherapy" Journal of Nanobiotechnology, 2024 Mar 13, 22:109 (IF 10.2) [Link]

[47] Jongyoon Shinn1, Seojeong Park1, Seonju Lee, Nayoon Park, Seojeong Kim, Seohui Hwang, James J. Moon, Young Joo Kwon, and Yonghyun Lee* "Anti-oxidative Hyaluronic acid-bilirubin Nanomedicine targeting Activated Hepatic Stellate Cells for Anti-hepatic Fibrosis Therapy" ACS Nano, 2024 Jan 31, 18(6):4704-4716 (IF 18.027)  1These authors contributed equally to this work. [Link]

2023

[46] Yonghyun Lee*, Jongyoon Shinn, Cheng Xu, Nouri Neamati, and James Moon*. “Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy” Nature Communication, 2023 Aug 08, 14:4771 (IF 17.694) *Co-corresponding authors [Link]

2022

[45] Jongyoon Shinn1, Juyeon Lee1, Seon Ah Lee, Seon Ju Lee, Yejin Kim, Joohyeon Kim, Jonghee Choi, Byungchae Jung, Taeho Kim, HyeonTaek Nam, Ah Hyun Choi, Hyungjun Kim*, and Yonghyun Lee*. “Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease” Pharmaceutics, 2022 Sep 19, 14(9), 1969: (IF 6.525).  1These authors contributed equally to this work. [Link]

[44] Jongyoon Shinn1, Nuri Kwon1, Seon Ah Lee, and Yonghyun Lee*. “Smart pH-Responsive Nanomedicines for Disease Therapy” Journal of Pharmaceutical Investigation, 2022 May 09: (IF 5.5) [Link]  **Featured by Ewha COP news [Link].

2021

[43] Yonghyun Lee*, Nobuhiko Kamda, and James Moon*. “Oral Nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome” Advanced Drug Delivery Reviews, 2021 Dec 01: 179: 114021 (IF 17.873) [Link] *Co-corresponding authors 

[42] Jongyoon Shinn1, Sunyoung Lee1, Hyon Kyong Lee1, Jaeeun Ahn1, Seon Ah Lee, Seonju Lee, and Yonghyun Lee*. “Recent Progress in Development and Applications of Second Near-infrared (NIR-II) Nanoprobes” Archives of Pharmacal Research, 2021 Feb 04: 44: 165-181. (IF 6.010) 1These authors contributed equally to this work. [Link]  **Featured by Ewha COP news [Link], KPAnews [Link]

2020

[41] Yonghyun Lee*, Jungyun Kim, Wooseong Kim, In-Soo Yoon, and Yunjin Jung*. “Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetics and Therapeutic Properties of Celecoxib” Pharmaceutics, 2020 Oct 30: 12(11), 1043, 1-13 (IF 6.525) *Co-corresponding authors. [Link]

[40] Cheng Xu, Hao Hong, Yonghyun Lee, Kyung Soo Park, Mingjiao Sun, Tianuri Wang, Marisa E Aikins, Yao Xu, and James J Moon. “Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets.” ACS Nano, 2020 Sep 9. (IF 15.881) [Link]

[39] Dong Yun Lee, Sukmo Kang, Yonghyun Lee, Jin Yong Kim, Dohyun Yoo, Wonsik Jung, Soyoung Lee, Yong Yeon Jeong, Kwangyeol Lee, and Sangyong Jon. "PEGylated bilirubin-coted Iron Oxide Nanoparticles as a Biosensor for Magnetic Relaxation Switching-based ROS detection in Whole Blood." Theranostics. 2020 Jan 12:10 (5): 1997-2007. (IF 11.546) [Link]

[38] Yonghyun Lee, Kohei Sugihara, Merritt G. Gilliland III, Sangyong Jon, Nobuhiko Kamada, and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” Nature Materials. 2020 Jan 1: 19 (1): 118-126. (IF 43.841)  [Link] **Featured by New England Journal of Medicine (NEJM) [Link], Nature Materials [Link]

2016 - 2019

[37] Byeongjun Yu, Dobeen Hwang, Hyungsu Jeon, Hyungjun Kim, Yonghyun Lee, Hyeongseop Keum, Jinjoo Kim, Dong Yun Lee, Yujin Kim, Junho Chung, Sangyong Jon. "A hybrid platform based on a bispecific peptide-antibody complex for targeted cancer therapy" Angewantde chemie. 2019 Feb 11:58(7):2005-2019 (IF 12.257)

[36] Hyungjun Kim, Dobeen Hwang, Minsuk Choi, Soyoung Lee, Sukmo Kang, Yonghyun Lee, Sunghyun Kim, Junho Chung, and Sangyong Jon. “Antibody-assisted delivery of a peptide-drug conjugate for targeted cancer therapy” Molecular Pharmaceutics. 2018 Dec 6:16(1):165-172 (IF 4.396)

[35] Joon Nam*, Yonghyun Lee*, Yejin Yang, Seongkeun Jung, Wooseong Kim, Jin-Wook Yoo, Jeon-Ok Moon, Changyong Lee, Hae Young Chung, Minsoo Kim, Sangyong Jon, and Yunjin Jung. “Is it worth expending energy to convert biliverdin into bilirubin?” Free Radical Biology and Medicine. 2018 Aug 20;124:232-240. (IF 5.657). *These authors contributed equally to this work.

[34] Soyoung Lee, Yonghyun Lee, Hyungjun Kim, Dongyun Lee and Sangyong Jon. “Bilirubin nanoparticle-assisted delivery of a small molecule-drug conjugate for targeted cancer therapy” Biomacromolecules. 2018 Jun 11;19(6):2270-2277. (IF 5.667)

[33] Yonghyun Lee, Soyoung Lee, and Sangyong Jon. “Biotinylated bilirubin nanoparticles as a tumor microenvironment-responsive drug delivery system for targeted cancer therapy” Advanced Science. 2018 Apr 24; 5(6):1800017. (IF 15.804).

[32] Dong Yun Lee, Jin Yong Kim, Yonghyun Lee, Soyoung Lee, Wenjun Miao, Hyeon Sik Kim, Jung-Joon Min, and Sangyong Jon. “Black pigment gallstone-inspired platinum-chelated bilirubin nanoparticles for combined photoacoustic imaging and photothermal therapy of cancers” Angewantde chemie. 2017 Oct 23:56(44):13684-13688. (IF 12.257)

[31] Dong-eon Kim*, Yonghyun Lee*, Mingyo Kim, Soyoung Lee, Sangyong Jon, and Seung-Hyo Lee. “Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma” Biomaterials. 2017 Sep;140:37-44. (IF 10.273). *These authors contributed equally to this work.

[30] Sookjin Kang*, Wooseong Kim*, Seongkeun Jeong*, Yonghyun Lee*, Joon Nam, Sunyoung Lee and Yunjin Jung. “Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: Implication in anti-inflammatory actions of 5-aminosalicylic acid” Free Radical Biology and Medicine. 2017 Jul;108:715-724. (IF 6.202). *These authors contributed equally to this work.

[29] Min Jun Kim, Yonghyun Lee, Sangyong Jon and Dong Yun Lee. “PEGylated bilirubin nanoparticles as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation” Biomaterials. 2017 Jul;133:242-252. (IF 10.273).

[28] Jin Yong Kim, Dong Yun Lee, Sukmo Kang, Wenjun Miao, Hyungjun Kim, Yonghyun Lee and Sangyong Jon. “Bilirubin nanoparticles preconditioning protects against hepatic ischemia-reperfusion injury.” Biomaterials. 2017 Jul;133:1-10. (IF 10.273).

[27] Yonghyun Lee, Sunghyun Kim, Daejin Kim, and Sangyong Jon “A histone H1-binding-aptide–based apoptosis imaging probe for monitoring tumor responses to cancer therapy” MedChemComm. 2017 Jan 5;8(2):390-393 (IF 2.394).

[26] Hyungjun Kim, Yonghyun Lee, Sukmo Kang, Minsuk Choi, Jinju Lee, Vipul Gujrati, and Sangyong Jon. “self-assembled nanoparticles comprised of aptide-SN38 conjugates for targeted cancer therapy.” Nanotechnology. 2016 Dec 2;27(48):48LT01. (IF 3.399).

[25] Wenjun Miao, Hyungjun Kim, Vipul Gujrati, Jinyong Kim, Hyungsu Jeon, Yonghyun Lee, Minsuk Choi, Jinjoo Kim, Soyoung Lee, Dongyun Lee, Sukmo Kang, and Sangyong Jon. “Photo-decomposable Organic Nanoparticles for Combined Tumor Optical Imaging and Multiple Phototherapies” Theranostics. 2016 Oct 1;6(13):2367-2379. (IF 8.063).

[24] Yonghyun Lee, Soyoung Lee, Dong Yun Lee, Byeongjun Yu, Wenjun Miao, and Sangyong Jon “Multi-stimuli-responsive bilirubin nanoparticles for anticancer therapy.” Angewandte chemie. 2016 Aug 26;55(36):10676-10680. (IF 12.257). Selected by the editors of Angewandte Chemie as a “Hot paper” (top 10% of all Angewandte publications).

[23] Yonghyun Lee, Hyungjun Kim, Sukmo Kang, Jinju Lee, Jinho Park, and Sangyong Jon. “Bilirubin nanoparticles as a nanomedicine for anti-inflammation therapy.” Angewantde chemie. 2016 Jun 20;55(26):7460-7463. (IF 12.257)

[22] Jinju Lee, Phei Er Saw, Vipul Gujrati, Yonghyun Lee, Hyungjun Kim, Sukmo Kang, Minsuk Choi, Jinjoo Kim, Jae-Il Kim, and Sangyong Jon. “Mono-arginine cholesterol-based small lipid nanoparticles as a systemic siRNA delivery platform for effective cancer therapy.” Theranostics. 2016 Jan 1;6(2):192-203. (IF 8.063)

2013 - 2015 

[21] Sunyoung Lee*, Yonghyun Lee*, Wooseong Kim, Joon Nam, Seongkeum Jeong, Jin-Wook Yoo, Minsoo Kim, Hyung Ryong Moon, and Yunjin Jung. “Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on NF kappaB, an anti-inflammatory target.” Drug Design, Development and Therapy. 2015 Aug 7;9:4227-4237. (IF 3.208) *These authors contributed equally to this work.

[20] Yonghyun Lee, Jungyoon Kim, Wooseong Kim, Joon Nam, Seongkeum Jeong, Sunyoung Lee, Jin-Wook Yoo, Minsoo Kim, and Yunjin Jung. “Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.” Drug Design, Development and Therapy. 2015 Jul 30;9:4105-4113. (IF 3.208)

[19] Wooseong Kim*, Yonghyun Lee*, Seongkeun Jeong, Joon Nam, Sunyoung Lee, and Yunjin Jung. “Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.” Archives of pharmacal research. 2015 Oct;38(10):1830-1838. (IF 2.458) *These authors contributed equally to this work.                                                                                          

[18] Sunghyun Kim, Daejin Kim, Yonghyun Lee, Byung-Heon Lee, and Sangyong Jon. “Conversion of low-affinity to high-affinity peptide by a beta-hairpin scaffold-assisted approach.” ChemBioChem. 2015 Jan 2;16(1):43-46. (IF 2.593)

[17] Hyungjun Kim, Eunhye Lee, In-Hyun Lee, Jinju Lee, Jinjoo Kim, Sunghyun Kim, Yonghyun Lee, Daejin Kim, Minsuk Choi, Yong-Chul Kim, and Sangyong Jon. “Preparation and therapeutic evaluation of paclitaxel-conjugated low-molecular-weight chitosan nanoparticles.” Macromol Res. 2014 Aug;22(8):805-808 (IF 1.758)

[16] Hyungjun Kim, Yonghyun Lee, In-Hyun Lee, Sunghyun Kim, Daejin Kim, Phei Er Saw, Jinju Lee, Minsuk Choi, Yong-Chul Kim, and Sangyong Jon. “Synthesis and therapeutic evaluation of an aptide–docetaxel conjugate targeting tumor-associated fibronectin.” Journal of controlled release. 2014 Mar 28;178:118-124. (IF 7.901)

[15] Yonghyun Lee, Wooseong Kim, Sungchae Hong, Huijeong Park, Soohwan Yum, Jeong-Hyun Yoon, and Yunjin Jung. “Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.” European journal of pharmacology. 2014 Mar 5;726 (1):49-56 (IF 3.17)

[14] Yonghyun Lee, Seongkeun Jeong, Wooseong Kim, Hyunjeong Kim, Jeong-Hyun Yoon, Seong Hoon Jeong, and Yunjin Jung. “Glycyrrhizin Enhances Therapeutic Activity of a Colon-Specific Methylprednisolone Prodrug Against Experimental Colitis.” Digestive diseases and sciences. 2013 May 1;58(5):1226-1234. (IF 2.937)

[13] Hyunsoo Kim, Tae Gan Son, Hee Ra Park, Yonghyun Lee, Yunjin Jung, Akihito ishigami, and Jaewon Lee. “Senescence marker protein 30 deficiency increases Parkinson`s pathology by impairing astrocyte activation.” Neurobiology of Aging. 2013 Apr 1;34(4):1177-1183. (IF 4.398)

2009 - 2012 

[12] Yonghyun Lee, Hyunjeong Kim, Wooseong Kim, Jeong-Hyun Yoon, Seong Hoon Jeong, and Yunjin Jung. “Colon-specific delivery of celecoxibis a potential strategy to improve toxicological and pharmacological properties of the selective COX-2 inhibitor: implication in treatment of familiar adenomatous polyposis.” Journal of drug targeting. 2012 Jul 1;20(6):524-534.( IF 3.227)

[11] Yonghyun Lee, Eun Hee Jung, Hyunjung Kim, Jeong-Hyun Yoon, Dae-Duk Kim, and Yunjin Jung. “Preparation and in vitro evaluation of celecoxib-amino acid conjugates as a colon specific prodrug.” Journal of Pharmaceutical Investigation. 2012 Jun 1

[10] Yonghyun Lee, Jeongyun Kim, Hyunjeong Kim, Sookjin Kang, Jeong-Hyun Yoon, Dae-Duk Kim, Young-Mi Kim, and Yunjin Jung. “N-succinylaspart-1-yl celecoxib is a potential colon specific prodrug of celecoxib with improved therapeutic properties.” Journal of pharmaceutical science. 2012 May 1;101(5):1831-1842. (IF 3.197)

[9] Hyunjeong Kim*, Yonghyun Lee*, Hansun Yoo, Jihye Kim, Hyesik Kong, Jeong-Hyun Yoon, Yunjin Jung, and Young-Mi Kim. “Synthesis and evaluation of sulfate conjugated metronidazole as a colon specific prodrug of metronidazole.” Journal of drug targeting. 2012 Apr 1;20(3):255-263. (IF 3.227) *These authors contributed equally to this work.

[8] Hyesik Kong, Yonghyun Lee, Hyunjeong Kim, Dae-Duk Kim, Jeong-Hyun Yoon, Yunjin Jung, and Young-Mi Kim. “Susceptibility of glucocorticoids to colonic metabolism and pharmacologic intervention in the metabolism: implication for therapeutic activity of colon-specific glucocorticoid 21-sulfate sodium at the target site.” Journal of pharmacy and pharmacology. 2012 Jan 1;64(1):128-138. (IF 2.39) 

[7] Hyesik Kong, Hyunjeong Kim, Heejeong Do, Yonghyun Lee, Sungchae Hong, Jeong-Hyun Yoon, Yunjin Jung, and Young-Mi Kim. “Structural effects of N-aromatic acyl-amino acid conjugates on their deconjugation in the cecal contents of rats: implication in design of a colon-specific prodrug with controlled conversion rate at the target site.” Biopharmaceutics & drug disposition. 2011 Nov 18;32(6):343-354. (IF 1.611)

[6] Yonghyun Lee, In Ho Kim, Jeongyun Kim, Jeong-Hyun Yoon, Young Hee Shin, Yunjin Jung, and Young-Mi Kim. “Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy.” Journal of drug targeting. 2011 Jul 8;19(5):336-343. (IF 3.227)

[5] Ji-Hye Kim, Jung-Yoon Kim, Yonghyun Lee, Young-Mi Kim, and Yunjin Jung. “Structural analysis of 5-aminosalicyl-L-glutamic Acid, a colon-specific prodrug of 5-aminosalicylic acid, for colon-specific deconjugation.” Journal of Pharmaceutical Investigation. 08/2010

[4] Hyesik Kong, Yonghyun Lee, Sungchae Hong, Jeongoh Han, Biom Choi, Yunjin Jung, and Young-Mi Kim. “Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis.” Journal of drug targeting. 2009 Jul 1;17(6):450-458. (IF 3.227)

[3] Hyo-Sik Kong, You-Na Lee, Yonghyun Lee, Young-Mi Kim, and Yunjin Jung. “Preparation and evaluation of microcrystallized cellulose xanthate-metal-oxytetracyclinecomplexes as antibacterial agents with prolonged antibacterial activity.” Journal of Pharmaceutical Investigation.

[2] Inho Kim, Hyesik Kong, Yonghyun Lee, Sungchae Hong, Jungoh Han, Sunhwa Jung, Yunjin Jung, and Young-Mi Kim. “Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine.” Pharm Res. 2009 Feb 1;26(2):415-421. (IF 3.896)

[1] Hyesik Kong*, Youngsoo Kim*, Yonghyun Lee*, Boim Choi, Sunhwa Jung, Yunjin Jung, and Young-Mi Kim. “Sulfate-conjugated methylprednisolone: Evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone.” Journal of drug targeting. 2009 Jan 1;17(2):159-167 (IF 3.227) *These authors contributed equally to this work.